Sensei Biotherapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.76
- Today's High:
- $0.825
- Open Price:
- $0.814
- 52W Low:
- $0.76
- 52W High:
- $2.1
- Prev. Close:
- $0.811
- Volume:
- 60430
Company Statistics
- Market Cap.:
- $26.58 million
- Book Value:
- 2.979
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.85%
- Return on Equity TTM:
- -44.08%
Company Profile
Sensei Biotherapeutics Inc had its IPO on 2021-02-04 under the ticker symbol SNSE.
The company operates in the Healthcare sector and Biotechnology industry. Sensei Biotherapeutics Inc has a staff strength of 23 employees.
Stock update
Shares of Sensei Biotherapeutics Inc opened at $0.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.76 - $0.83, and closed at $0.78.
This is a -3.82% slip from the previous day's closing price.
A total volume of 60,430 shares were traded at the close of the day’s session.
In the last one week, shares of Sensei Biotherapeutics Inc have slipped by -24.27%.
Sensei Biotherapeutics Inc's Key Ratios
Sensei Biotherapeutics Inc has a market cap of $26.58 million, indicating a price to book ratio of 0.4258 and a price to sales ratio of 0.
In the last 12-months Sensei Biotherapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-45691000. The EBITDA ratio measures Sensei Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sensei Biotherapeutics Inc’s operating margin was 0% while its return on assets stood at -25.85% with a return of equity of -44.08%.
In Q2, Sensei Biotherapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Sensei Biotherapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sensei Biotherapeutics Inc’s profitability.
Sensei Biotherapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3654. Its price to sales ratio in the trailing 12-months stood at 0.
Sensei Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $89.58 million
- Total Liabilities
- $5.36 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $29000
- Dividend Payout Ratio
- 0%
Sensei Biotherapeutics Inc ended 2024 with $89.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $89.58 million while shareholder equity stood at $79.20 million.
Sensei Biotherapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $5.36 million in other current liabilities, 3000.00 in common stock, $-217357000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.23 million and cash and short-term investments were $78.84 million. The company’s total short-term debt was $2,313,000 while long-term debt stood at $0.
Sensei Biotherapeutics Inc’s total current assets stands at $81.07 million while long-term investments were $0 and short-term investments were $68.61 million. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Sensei Biotherapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $29000.
Comparatively, Sensei Biotherapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.78
- 52-Week High
- $2.1
- 52-Week Low
- $0.76
- Analyst Target Price
- $5.33
Sensei Biotherapeutics Inc stock is currently trading at $0.78 per share. It touched a 52-week high of $2.1 and a 52-week low of $2.1. Analysts tracking the stock have a 12-month average target price of $5.33.
Its 50-day moving average was $1.14 and 200-day moving average was $1.39 The short ratio stood at 9.35 indicating a short percent outstanding of 0%.
Around 3849.3% of the company’s stock are held by insiders while 1174.7% are held by institutions.
Frequently Asked Questions About Sensei Biotherapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company’s pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.